Condition: Gallbladder Cancer · Sponsor: Banaras Hindu University
Gallbladder cancer (GBC) is the most common malignant tumour of the biliary tract. It is also the most aggressive cancer of the biliary tract with the shortest median survival from the time of diagnosis. Currently, radical resection is the most effective strategy to potentially cure GBC. Chemotherapy and radiotherapy have been employed as adjuvant and palliative setting, however, the overall survival is still dismal. This study aim to evaluate the addition of Everolimus in addition to standard of care in gallbladder cancer.
This description comes directly from the study's public registry record.
Manoj Pandey · +91-542-2369332 · mpandey66@bhu.ac.in
Madhumita Tripathi · mishthi2018@gmail.com
Always discuss trial participation with your own doctor first.
| Banaras Hindu University | Varanasi, Uttar Pradesh, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05833815